Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 9/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23908890 | 0.97 | S1PR2 (0.66) | S1PR2KDM4EHSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL23909010 | 0.94 | S1PR2 (0.60) | S1PR2KDM4EHSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL23908729 | 0.92 | S1PR2 (0.60) | S1PR2KDM4EHSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL23908969 | 0.91 | S1PR2 (0.67) | S1PR2KDM4EHSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL23966642 | 0.91 | S1PR2 (0.63) | S1PR2KDM4EHSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL23914678 | 0.91 | S1PR2 (0.56) | S1PR2KDM4ESMN1; SMN2NPSR1TDP1 | |
| SCHEMBL23908759 | 0.91 | S1PR2 (0.58) | S1PR2KDM4ESMN1; SMN2TP53 | |
| SCHEMBL23908790 | 0.90 | S1PR2 (0.61) | S1PR2KDM4EHSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL23908736 | 0.90 | S1PR2 (0.61) | S1PR2KDM4EHSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL23908732 | 0.90 | S1PR2 (0.71) | S1PR2KDM4EHSD17B10MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885KDM4E 3835/4885HSD17B10 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.